This article is more than 5 years old. Information may no longer be current.

Eleven Biotherapeutics reports increase in revenue in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eleven Biotherapeutics reported total revenue of $2.2 million in 2014 compared with $1.3 million in 2013, according to a press release.

Net loss applicable to common stockholders was reported at $34.7 million, or $2.37 per share, in 2014 compared with $21.9 million, or $16.18 per share, in 2013.

Research and development expenses were reported at $26.7 million in 2014 compared with $13.8 million in 2013. General and administrative expenses were reported at $8.5 million in 2014 compared with $4 million in 2013.